title: Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
abstract: The aims of this study were to investigate the effect of chinonin in preventing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration in C57BL/6 mice and to examine the possible mechanisms. The neurotoxin MPTP was employed to create a subacute Parkinson's disease (PD)-like model in C57BL/6 mice. Chinonin (10, 20, 40 mg/kg body weight) was intraperitoneally administered 0.5 h after MPTP (30 mg/kg) injection for 7 d consecutively. Chinonin showed neuroprotective effects in the MPTP-treated mice PD model by ameliorating motor impairment in the catwalk and open-field tests. Consistently, chinonin reduced loss of dopaminergic neurons in the substantia nigra and prevented depletion of dopamine and its metabolites 3-methoxy-4-hydroxy-phenylacetic acid and homovanillic acid in the striatum of mice. Compared with the MPTP group, in the chinonin plus MPTP groups significant increases of superoxide dismutase activity and glutathione levels were observed as well as a distinct reduction of lipid peroxidation product malondialdehyde in the striatum. Taken together, we propose that chinonin exerts neuroprotective effects in C57BL/6 mouse model of PD and these effects may be due to chinonin's antioxidative property.
authors.affiliation: College of Pharmacy, Jinan University.
authors.forename: Guoshuai
authors.initials: G
authors.lastname: Feng
authors.forename: Zhijian
authors.initials: Z
authors.lastname: Zhang
authors.forename: Qingqing
authors.initials: Q
authors.lastname: Bao
authors.forename: Zaijun
authors.initials: Z
authors.lastname: Zhang
authors.forename: Libing
authors.initials: L
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Jiang
authors.forename: Sha
authors.initials: S
authors.lastname: Li
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D005684:Gait / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009498:Neurotoxins; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D013378:Substantia Nigra / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism; D044004:Xanthones / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D009498:Neurotoxins; D044004:Xanthones; D015102:3,4-Dihydroxyphenylacetic Acid; C013592:mangiferin; D008315:Malondialdehyde; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D013482:Superoxide Dismutase; D005978:Glutathione; D004298:Dopamine; D006719:Homovanillic Acid